MECLON ® Clotrimazole + Metronidazole

MECLON ® is a drug based on Clotrimazole + Metronidazole

THERAPEUTIC GROUP: Gynecological antimicrobials and antiseptics - association of imidazole derivatives

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications MECLON ® Clotrimazole + Metronidazole

MECLON ® is indicated in the treatment of symptoms associated with vaginal infections, in particular cervico-vaginitis and vulvar vaginitis, supported by microorganisms sensitive to Clotrimazole and Metronidazole.

Mechanism of action MECLON ® Clotrimazole + Metronidazole

MECLON ® combines two particularly effective active ingredients in the treatment of gynecological infections thus ensuring a significant extension of the action spectrum with an effective enhancement of antiprotozoal and antifungal activity.

In fact, the association of Clotrimazole and Metronidazole allows MECLON ® to be active against Gram positive and Gran negative bacteria, protozoa such as Trichomonas vaginalis and Toxoplasma, fungi such as Candida while sparing vaginal flora, important in supporting the mechanisms of defense against the penetration of pathogens.

From the molecular point of view:

Metronidazole acts by forming reactive complexes with the DNA of the pathogenic element, thus inhibiting the proliferative and biosynthetic mechanisms of the microorganism;
Clotrimazole instead exerts an inhibiting action against the? Enzyme 14 alfa sterol dimethylase, blocking the synthesis of? Ergosterol, a key element in the structuring of the plasma membrane of fungi and at the same time favoring the? Accumulation of potentially harmful intermediates for the cellular activities of the microorganism.

All this takes the form of a significant antimicrobial action effective even in cases of mixed infections.

Studies carried out and clinical efficacy

CLOTRIMAZOLE AND METRONIDAZOLE IN THE TREATMENT OF RESISTANT T.VAGINALIS INFECTIONS

Int J STD AIDS. 2005 Jul; 16 (7): 488-90.

Very interesting study that shows how the association between clotrimazole and metronidazole can be effective also in the treatment of infections caused by T.Vaginalis strains generally resistant to metronidazole therapy.

CLOTRIMAZOLE-METRONIDAZOLE: clinical experience

Minerva Ginecol. 1984 Jan-Feb; 36 (1-2): 47-57.

Dated study that includes the clinical experience in the treatment of vaginal mixed infections by combining imidazole derivatives such as Clotrimazole and Metronidazole, emphasizing the efficacy of this dual therapy compared to the monotherapies.

CHLORIMAZOL + METRONIDAZOLE IN THE TREATMENT OF T.VAGINALIS INFECTIONS

J Chemother. 1996 Apr; 8 (2): 96-101.

Work demonstrating the greater efficacy in treating infections due to Trichomonas vaginalis, than the association between metronidazole + clotrimazole compared to metronidazole monotherapy.

Method of use and dosage

MECLON ®

100 mg vaginal ovules of Clotrimazole + 500 mg of Metronidazole;

Cream for vaginal use with 20% of Metronidazole and 4% of Clotrimazole;

Vaginal solution containing 200 mg of Clotrimazole and 1 g of Metronidazole per 130 ml bottle.

MECLON ® must be used under strict medical supervision, so that the dosages and the relative therapeutic schemes can be the most effective.

Generally, for the treatment to be effective it is necessary to prolong the therapy for at least 6 days, taking care to possibly extend the coverage also to the partner for preventive purposes.

The modalities of "assumption" vary according to the chosen format and to the medical indications, although in all cases recourse is had to the daily single administration deeply in the vagina.

In certain cases, therapy with MECLON ® should be accompanied by oral therapy to observe a significant improvement in the patient's clinical condition.

Warnings MECLON ® Clotrimazole + Metronidazole

Before undertaking the intake of MECLON ® it would be advisable to consult your doctor with whom to consider the appropriateness of the chosen therapy.

Prolonged use of this drug could cause hypersensitivity reactions; therefore if the patient should observe unwanted signs or symptoms he should immediately inform his doctor, taking into consideration the possibility of suspending the therapy in progress.

MECLON ® in vaginal solution contains among its excipients p-hydroxybenzoates, elements with a high allergenic power.

The use of MECLON ® during menstruation is not recommended.

PREGNANCY AND BREASTFEEDING

The absence of studies able to characterize the safety profile of the drug for fetal health greatly limits the use of MECLON ® during pregnancy and in the subsequent period of breastfeeding.

Therefore in the above phases of life it would be advisable to consult your doctor or gynecologist.

Interactions

No clinically relevant drug interactions are currently known.

Contraindications MECLON ® Clotrimazole + Metronidazole

MECLON ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients.

Undesirable effects - Side effects

The use of MECLON ® is generally safe and well tolerated, exposing the patient, only rarely, to local reactions such as irritation, scaling, itching and burning.

In a few cases, the appearance of more serious hypersensitivity reactions such as hives, dyspnea and hypotension was also observed.